Compare Alcon AG (ALC) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Sibanye Stillwater Ltd — how do they compare? Alcon AG trades at $73.81 (market cap $36.44B), while Sibanye Stillwater Ltd trades at $10.72 (market cap $7.54B). The key difference: Alcon AG is far larger — about 4.8× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| ALC | SBSW | |
|---|---|---|
Market Cap | $36.44B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $90.12 | $21.12 |
52-Week Low | $62.02 | $7.27 |
Enterprise Value | $40.28B | $9.19B |
Dividend Yield | 0.48% | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
Sibanye Stillwater (SBSW) trades at $10.74, up 0.66% with a bullish technical signal. The company shows mixed fundamentals with a negative net income margin of -3.99% but strong operating cash flow of $10.11B in 2024. Recent earnings misses and declining revenue since 2021 highlight challenges, though analyst consensus remains positive with a $14.25 price target. Technical indicators show overbought RSI levels but strong moving average support.
SBSW presents a high-risk opportunity with significant upside potential if management executes on debt reduction and operational improvements. Key risks include persistent negative profitability, commodity price volatility, and execution challenges. The stock's deep value metrics (P/E of 4.76) contrast with operational headwinds, requiring careful monitoring of quarterly execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
